Engineered immune cells for Hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment where your own immune cells are modified to better attack Hodgkin lymphoma cells. It is for people whose disease has not responded to other therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have classical Hodgkin lymphoma.
- You are well enough to be up and about (Karnofsky score above 60%).
- You haven't had major surgery in the last 28 days.
- You haven't had other experimental treatments or chemotherapy/radiation in the last 3 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
This trial tests a new type of immune cell therapy using cord blood cells that are grown to attack cancer cells. It is for people with certain blood cancers (lymphoma or acute lymphoblastic leukemia) that have come back or not responded to standard treatments.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This trial tests whether adding a type of immune-boosting drug (called checkpoint inhibitor immunotherapy) after high-dose chemotherapy and stem cell transplant helps people with Hodgkin lymphoma that has returned or didn't respond to initial treatment. The goal is to see if this combination works better than chemotherapy and transplant alone.
This trial tests a new treatment where your own immune cells are modified to find and attack CD7-positive T-cell lymphoma cells. It is for people whose lymphoma has not responded to standard treatments.
This trial is looking at new ways to predict how Hodgkin lymphoma will respond to treatment. It collects blood and tumor samples at key times to see if these can help doctors make better treatment decisions in the future.
Hear when a new Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.